Judge, D. P., Alexander, K. M., Cappelli, F., Fontana, M., Garcia-Pavia, P., Gibbs, S. D. J., Grogan, M., Hanna, M., Masri, A., Maurer, M. S., Obici, L., Soman, P., Cao, X., Lystig, T., Tamby, J.-F., Siddhanti, S., Castaño, A., Katz, L., Fox, J. C., … Gillmore, J. D. (2025). Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy. Journal of the American College of Cardiology, 85(10), 1003–1014. https://doi.org/10.1016/j.jacc.2024.11.042

Gonzalez-Lopez, E., Maurer, M. S., & Garcia-Pavia, P. (2025). Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine. European Heart Journal. https://doi.org/10.1093/eurheartj/ehae811

Fontana, M., Maurer, M. S., Gillmore, J. D., Bender, S., Jay, P. Y., & Solomon, S. D. (2025). Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2024.10.097

Folkvaljon, F., Gertz, M., Gillmore, J. D., Khella, S., Masri, A., Maurer, M. S., Cruz, M. W., Wixner, J., Chen, J., Reicher, B., Kwoh, J., Yarlas, A., & Berk, J. L. (2024). Estimating Meaningful Differences in Measures of Neuropathic Impairment, Health‐Related Quality of Life, and Nutritional Status in Patients With Hereditary Transthyretin Amyloidosis. Muscle & Nerve, 71(1), 96–107. Portico. https://doi.org/10.1002/mus.28299

Fontana, M., Maurer, M. S., Gillmore, J. D., Bender, S., Aldinc, E., Eraly, S. A., Jay, P. Y., & Solomon, S. D. (2024). Outpatient Worsening Heart Failure in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2024.11.015

Liou, L., Maurer, M. S., & Kontorovich, A. R. (2024). Improved Access to Genetics Care is Needed to Address Health Inequities in ATTRv Amyloidosis. Circulation, 150(14), 1072–1074. https://doi.org/10.1161/circulationaha.124.070525

Maurer, M. S., Soman, P., Hernandez, A., Garcia-Pavia, P., Signorovitch, J., Wei, L. J., Hanna, M., Ruberg, F. L., Kittleson, M., Kazi, D., Dorbala, S., Hsu, K., Lousada, I., Adigun, R., Dunnmon, P., Kelly, J., Gillmore, J., Masri, A., … Sanjurjo, V. (2024). Advancing Transthyretin Amyloidosis Drug Development in an Evolving Treatment Landscape: Amyloidosis Forum Meeting Proceedings. Advances in Therapy, 41(7), 2723–2742. https://doi.org/10.1007/s12325-024-02891-0

Shetty, N. S., Pampana, A., Patel, N., Maurer, M. S., Goyal, P., Li, P., Arora, G., & Arora, P. (2024). Carpal Tunnel Syndrome and Transthyretin Amyloidosis in the All of Us Research Program. Mayo Clinic Proceedings, 99(7), 1101–1111. https://doi.org/10.1016/j.mayocp.2023.11.016

Petros, F. E., Santos, A. M., Adeniyi, A., Teruya, S., De Los Santos, J., Maurer, M. S., & Agrawal, S. K. (2024). Gait abnormalities in older adults with transthyretin cardiac amyloidosis. Amyloid, 31(2), 116–123. https://doi.org/10.1080/13506129.2024.2319133

Datar, Y., Cuddy, S. A. M., Ovsak, G., Giblin, G. T., Maurer, M. S., Ruberg, F. L., Arnaout, R., & Dorbala, S. (2024). Myocardial Texture Analysis of Echocardiograms in Cardiac Transthyretin Amyloidosis. Journal of the American Society of Echocardiography, 37(5), 570–573. https://doi.org/10.1016/j.echo.2024.02.005

Garcia‐Pavia, P., Grogan, M., Kale, P., Berk, J. L., Maurer, M. S., Conceição, I., Di Carli, M., Solomon, S. D., Chen, C., Yureneva, E., Vest, J., & Gillmore, J. D. (2024). Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin‐mediated amyloidosis with polyneuropathy. European Journal of Heart Failure, 26(2), 397–410. Portico. https://doi.org/10.1002/ejhf.3138

Karam, C., Mauermann, M. L., Gonzalez‐Duarte, A., Kaku, M. C., Ajroud‐Driss, S., Brannagan, T. H., & Polydefkis, M. (2024). Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts. Muscle & Nerve, 69(3), 273–287. Portico. https://doi.org/10.1002/mus.28026

Coelho, T., Dispenzieri, A., Grogan, M., Conceição, I., Waddington-Cruz, M., Kristen, A. V., Wixner, J., Diemberger, I., Gonzalez-Moreno, J., Maurer, M. S., Planté-Bordeneuve, V., Garcia-Pavia, P., Tournev, I., Gonzalez-Costello, J., Cariou, E., González-Duarte, A., Glass, O., Chapman, D., … Amass, L. (2023). Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay. Amyloid, 30(4), 445–448. https://doi.org/10.1080/13506129.2023.2229484

Gentile, L., Coelho, T., Dispenzieri, A., Conceição, I., Waddington-Cruz, M., Kristen, A., Wixner, J., Diemberger, I., Gonzalez-Moreno, J., Cariou, E., Maurer, M. S., Planté-Bordeneuve, V., Garcia-Pavia, P., Tournev, I., Gonzalez-Costello, J., Duarte, A. G., Grogan, M., Mazzeo, A., … Chapman, D. (2023). A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Orphanet Journal of Rare Diseases, 18(1). https://doi.org/10.1186/s13023-023-02962-5

Wardhere, A., Bampatsias, D., Fine, N., Garcia-Pavia, P., Grogan, M., Kristen, A. V., Damy, T., Sekijima, Y., & Maurer, M. S. (2023). Heterogeneous worldwide access and pricing of Tafamidis. Amyloid, 31(1), 73–75. https://doi.org/10.1080/13506129.2023.2263620

Madhani, A., Sabogal, N., Massillon, D., Paul, L. D., Rodriguez, C., Fine, D., Helmke, S., Winburn, M., Kurian, D., Raiszadeh, F., Teruya, S., Cohn, E., Einstein, A. J., Miller, E. J., Connors, L. H., Maurer, M. S., & Ruberg, F. L. (2023). Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study. Journal of the American Heart Association, 12(15). https://doi.org/10.1161/jaha.122.028973

Smiley, D. A., Einstein, A. J., Mintz, A., Shetty, M., Chan, N., Helmke, S. T., Bhatia, K., Goldner, K., Brannagan, T. H., Santana, D. D., & Maurer, M. S. (2023). Gene Silencing Therapy in Hereditary (Variant) Transthyretin Cardiac Amyloidosis: A Puzzling Case of Decreasing Pyrophosphate Uptake on Scintigraphy. Circulation: Cardiovascular Imaging, 16(8). https://doi.org/10.1161/circimaging.123.015243

Rosenblum, H. R., Griffin, J. M., Minamisawa, M., Prasad, N., Vest, J., White, M. T., Solomon, S. D., Burkhoff, D., & Maurer, M. S. (2023). Effect of patisiran on stroke volume in hereditary transthyretin‐mediated amyloidosis: insights from pressure–volume analysis of the APOLLO study. European Journal of Heart Failure, 25(5), 727–736. Portico. https://doi.org/10.1002/ejhf.2783

Ruberg, F. L., Blaner, W. S., Chiuzan, C., Connors, L. H., Einstein, A. J., Fine, D., Helmke, S., Kurian, D., Pandey, S., Raiszadeh, F., Rodriguez, C., Sabogal, N., Teruya, S., Winburn, M., Chung, W. K., Cohn, E., Miller, E. J., Kelly, J. W., & Maurer, M. S. (2023). Design and Rationale the SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study. Journal of the American Heart Association, 12(8). https://doi.org/10.1161/jaha.122.028534

Saef, J., Martyn, T., Ives, L., Roth, L. R., Grodin, J. L., Maurer, M. S., Hanna, M., & Tang, W. H. W. (2023). Predictive Modeling to Assess Pretest Probability of Transthyretin Gene Variants Based on Demographic Information. Circulation: Heart Failure, 16(4). https://doi.org/10.1161/circheartfailure.122.009908

Brannagan, T. H., Berk, J. L., Gillmore, J. D., Maurer, M. S., Waddington‐Cruz, M., Fontana, M., Masri, A., Obici, L., Brambatti, M., Baker, B. F., Hannan, L. A., Buchele, G., Viney, N. J., Coelho, T., & Nativi‐Nicolau, J. (2022). Liver‐directed drugs for transthyretin‐mediated amyloidosis. Journal of the Peripheral Nervous System, 27(4), 228–237. Portico. https://doi.org/10.1111/jns.12519

Brannagan, T. H., Coelho, T., Wang, A. K., Polydefkis, M. J., Dyck, P. J., Berk, J. L., Drachman, B., Gorevic, P., Whelan, C., Conceição, I., Plante-Bordeneuve, V., Merlini, G., Obici, L., Plana, J. M. C., Gamez, J., Kristen, A. V., Mazzeo, A., Gentile, L., … Narayana, A. (2022). Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update. Journal of Neurology, 269(12), 6416–6427. https://doi.org/10.1007/s00415-022-11276-8

Maurer, M. S. (2022). Overview of Current and Emerging Therapies for Amyloid Transthyretin Cardiomyopathy. The American Journal of Cardiology, 185, S23–S34. https://doi.org/10.1016/j.amjcard.2022.10.014

Dispenzieri, A., Coelho, T., Conceição, I., Waddington-Cruz, M., Wixner, J., Kristen, A. V., Rapezzi, C., Planté-Bordeneuve, V., Gonzalez-Moreno, J., Maurer, M. S., Grogan, M., Chapman, D., Amass, L., Pavia, P. G., Tarnev, I., Costello, J. G., Briseno, M. A. G. D., Schmidt, H., … Zivkovic, S. (2022). Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update. Orphanet Journal of Rare Diseases, 17(1). https://doi.org/10.1186/s13023-022-02359-w

Cuddy, S. A., Datar, Y., Ovsak, G., Saith, S., Murphy, S. P., Bay, C. P., Haddad, M., Lilleness, B., Muralidhar, V., Pipilas, A., Vuong, J., Guardino, E., Maurer, M. S., Ruberg, F. L., Falk, R. H., & Dorbala, S. (2022). Optimal Echocardiographic Parameters to Improve the Diagnostic Yield of Tc-99m-Bone Avid Tracer Cardiac Scintigraphy for Transthyretin Cardiac Amyloidosis. Circulation: Cardiovascular Imaging, 15(11). https://doi.org/10.1161/circimaging.122.014645

Barroso, F. A., Coelho, T., Dispenzieri, A., Conceição, I., Waddington-Cruz, M., Wixner, J., Maurer, M. S., Rapezzi, C., Planté-Bordeneuve, V., Kristen, A. V., González-Duarte, A., Chapman, D., Stewart, M., & Amass, L. (2022). Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS). Amyloid, 29(3), 175–183. https://doi.org/10.1080/13506129.2022.2043270

Poterucha, T. J., Kurian, D., Raiszadeh, F., Teruya, S., Elias, P., Kogan, R., Chiuzan, C., Einstein, A. J., Ruberg, F. L., & Maurer, M. S. (2022). Relation of Body Mass Index to Transthyretin Cardiac Amyloidosis Particularly in Black and Hispanic Patients (from the SCAN-MP Study). The American Journal of Cardiology, 177, 116–120. https://doi.org/10.1016/j.amjcard.2022.05.003

Batra, J., Rosenblum, H., Cappelli, F., Zampieri, M., Olivotto, I., Griffin, J. M., Saith, S. E., Teruya, S., De Los Santos, J., Argiro, A., Burkhoff, D., Perfetto, F., & Maurer, M. S. (2022). Racial Differences in Val122Ile-Associated Transthyretin Cardiac Amyloidosis. Journal of Cardiac Failure, 28(6), 950–959. https://doi.org/10.1016/j.cardfail.2021.12.016

Obi, C. A., Mostertz, W. C., Griffin, J. M., & Judge, D. P. (2022). ATTR Epidemiology, Genetics, and Prognostic Factors. Methodist DeBakey Cardiovascular Journal, 18(2), 17–26. https://doi.org/10.14797/mdcvj.1066

Parcha, V., Malla, G., Irvin, M. R., Armstrong, N. D., Judd, S. E., Lange, L. A., Maurer, M. S., Levitan, E. B., Goyal, P., Arora, G., & Arora, P. (2022). Association of Transthyretin Val122Ile Variant With Incident Heart Failure Among Black Individuals. JAMA, 327(14), 1368. https://doi.org/10.1001/jama.2022.2896

Griffin, J. M., Baughan, E., Rosenblum, H., Clerkin, K. J., Fried, J. A., Raikhelkar, J., Uriel, N., Brannagan, T. H., Takeda, K., Grodin, J. L., Marboe, C., Maurer, M. S., & Farr, M. A. (2022). Surveillance for disease progression of transthyretin amyloidosis after heart transplantation in the era of novel disease modifying therapies. The Journal of Heart and Lung Transplantation, 41(2), 199–207. https://doi.org/10.1016/j.healun.2021.10.007